IPIX >> based on a few PMs i've rec'd in this week .. i

New Post Public Reply Private Reply Replies (2) Message Board
4kids 4kids #3690
296
IPIX >> based on a few PMs i've rec'd in this week .. i want to show the first 3 MMs' who *factually* reported activity to Finra since this time last year .. May 2017 to April 2018 .. as well as the number of MMs' *participating per month* and *volume by month*

you can clearly see who the PRIMARY/SECONDARY and TERTIARY MMs' are re: IPIX

this is important in understanding the role decoys' play in regards to what l2 *shows* on any given day but mostly as is always the case with an OTC SURVIVOR .. what is revealed over weeks/months and in some cases .. years

that is why i can note which MM .. is usually acting as a decoy on l2 ..

note exactly the volume done per month (which is why you can see these same
Marker Manipulators lying in regards to *avg* daily volume (as was just noted
yesterday via *legal* as being in the 500k range) .. is factually false .. it's closer
to 200k on any given week recently .. but what is really worth noting is who doesn't deviate from the first 3 spots .. each and every month .. you can also observe the fact of *decoys* willing to play the UPSIDE DOWN GAME .. with MMs' (back in 2015 .. running 25 to 29) ..MMs now *reporting* between 9 to 11 for IPIX (13 for May 17 .. CTIX) .. is *actually decreasing*

as i've always noted *volume* tells the tale of where in the cycle NR and CEs *are*

today's volume again comes as no surprise .. they need *volume* to show
the only aspect that matters today is where they close IPIX .. and what gets marked .. as i've noted .. this effort i refer to as resets r possible (resetting trades
via those who do)

most can figure out this will relo UP the 10 and 90 avgs .. but will a price (daily reg sho %) have to be paid?

the other fact that can't be ignored to suit is the %s' posted by only 3 MMs every month .. since May 2017 .. 69% to 87% reveals why the round robining rotation of *volume* reported is well in hand by just 3 MMs CONtinues to ramp upwards

make no mistake an educated retail investor is a colluding entity's worst NITE mare (pun intended)


APRIL 2018 .. IPIX Volume ~ 4,473,436
10 MMs' reporting ..
( ETRF/NITE @ 27% .. CDEL @ 20% ) .. total = 75.16% of *volume*
( ARCA .. OTCX .. CSTI @ 9% .. 8% and 4% )
( CANT .. LAFC .. PUMA .. STXG all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 
IPIX Innovation Pharma 4,473,436 4,078,577 17,073,621 ETRF G1 EXECUTION SVCsETRF, LLC 1,240,454 1 27.73%
IPIX Innovation Pharma 4,473,436 4,078,577 17,073,621 NITE VIRTU AMERICAS LLC 1,216,167 2 27.19%
IPIX Innovation Pharma 4,473,436 4,078,577 17,073,621 CDEL CITADEL SECURITIES LLC 905,353 3 20.24%


MARCH 2018 .. IPIX Volume ~ 4,078,577
11 MMs' reporting
( ETRF/CDEL/NITE @ 30% ..24% .. 22% ) .. total = 77.55% of *volume*
( ARCA & CSTI @ 10% and 5% )
( OTCX .. LAFC .. CANT .. VERT .. MAXM .. PUMA all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	4,078,577	3,388,387	12,600,185	ETRF	G1 EXECUTION SVCs, LLC	1,247,854	1	30.6% 
IPIX Innovation Pharma 4,078,577 3,388,387 12,600,185 CDEL CITADEL SECURITIES LLC 1,004,220 2 24.62%
IPIX Innovation Pharma 4,078,577 3,388,387 12,600,185 NITE VIRTU AMERICAS LLC 910,681 3 22.33%


FEBRUARY 2018 .. IPIX Volume ~ 3,388,387
10 MMs' reporting ..
( ETRF @ 34% .. NITE & CDEL @ 24% ) .. total = 83.04% of *volume*
( ARCA .. CSTI .. LAFC @ 6% .. 4% and 3% )
( CANT .. VERT .. PUMA .. VNDM all sub 2% )


Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	3,388,387	5,133,221	8,521,608	ETRF	G1 EXECUTION SVCs, LLC	1,152,418	1	34.01% 
IPIX Innovation Pharma 3,388,387 5,133,221 8,521,608 NITE VIRTU AMERICAS LLC 838,168 2 24.74%
IPIX Innovation Pharma 3,388,387 5,133,221 8,521,608 CDEL CITADEL SECURITIES LLC 822,921 3 24.29%


JANUARY 2018 .. IPIX Volume ~ 5,133,221
9 MMs' reporting ..
( NITE @ 33% .. ETRF @ 25% .. CDEL @ 23% ) .. total = 82.27% of *volume*
( ARCA .. CSTI .. LAFC @ 6% .. 5% .. 2% )
( CANT .. PUMA .. MAXM .. all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	5,133,221	8,121,069	5,133,221	NITE	VIRTU AMERICAS LLC	1,721,407	1	33.53% 
IPIX Innovation Pharma 5,133,221 8,121,069 5,133,221 ETRF G1 EXECUTION SVCs, LLC 1,296,054 2 25.25%
IPIX Innovation Pharma 5,133,221 8,121,069 5,133,221 CDEL CITADEL SECURITIES LLC 1,206,032 3 23.49%


DECEMBER 2017 .. IPIX Volume ~ 8,121,069
11 MMs' reporting ..
( NITE @ 35% .. CDEL @ 23% .. ETRF @ 18% ) .. total = 76.89% of *volume*
( ARCA .. CSTI .. LAFC .. CANT @ 8% .. 6% .. 3% .. 2% )
( VERT .. MAXM .. INTL .. PUMA all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	8,121,069	4,031,082	62,497,265	NITE	VIRTU AMERICAS LLC	2,886,476	1	35.54% 
IPIX Innovation Pharma 8,121,069 4,031,082 62,497,265 CDEL CITADEL SECURITIES LLC 1,896,344 2 23.35%
IPIX Innovation Pharmaceuticals Inc. Common Stock Other OTC 8,121,069 4,031,082 62,497,265 ETRF G1 EXECUTION SVCs, LLC 1,461,977 3 18%


NOVEMBER 2017 .. IPIX Volume ~ 4,031,082
11 MMs' reporting ..
( NITE @ 31% .. ETRF @ 25% .. CDEL @ 22% ) = total of 79.71% of *volume*
( VERT/CANT/ARCA/LAFC/CSTI .. @ 6% .. 4% .. 3% .. 3% .. 2% )
( PUMA .. MAXM .. AEXG all sub 1% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	4,031,082	3,856,915	54,376,196	NITE	VIRTU AMERICAS LLC	1,283,920	1	31.85% 
IPIX Innovation Pharma 4,031,082 3,856,915 54,376,196 ETRF G1 EXECUTION SVCs, LLC 1,032,596 2 25.62%
IPIX Innovation Pharma 4,031,082 3,856,915 54,376,196 CDEL CITADEL SECURITIES LLC 896,653 3 22.24%


OCTOBER 2017 .. IPIX Volume ~ 3,856,915
11 MMs' reporting ..
( NITE .. ETRF .. CDEL @ 33% .. 27% .. 25% ) .. total = 87.51% of *volume*
( LAFC .. CSTI .. VERT @ 3% .. 3% .. 2% )
( CANT .. STXG .. VNDM .. PUMA .. MAXM all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	3,856,915	2,395,379	50,345,114	NITE	VIRTU AMERICAS LLC	1,304,156	1	33.81% 
IPIX Innovation Pharma 3,856,915 2,395,379 50,345,114 ETRF G1 EXECUTION SVCs, LLC 1,068,898 2 27.71%
IPIX Innovation Pharma 3,856,915 2,395,379 50,345,114 CDEL CITADEL SECURITIES LLC 1,002,365 3 25.99%


SEPTEMBER 2017 .. IPIX Volume ~ 2,395,379
9 MMs' reporting ..
( NITE .. ETRF .. CDEL @ 33% .. 25% .. 21% ) .. total = 80.32% of *volume*
( VERT .. CSTI .. CANT @ 12% .. 3% .. 2% )
( LAFC .. ARCA .. PUMA all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	2,395,379	3,276,355	46,488,199	NITE	VIRTU AMERICAS LLC	807,293	1	33.7% 
IPIX Innovation Pharmaceuticals Inc. Common Stock Other OTC 2,395,379 3,276,355 46,488,199 ETRF G1 EXECUTION SVCs, LLC 603,325 2 25.19%
IPIX Innovation Pharmaceuticals Inc. Common Stock Other OTC 2,395,379 3,276,355 46,488,199 CDEL CITADEL SECURITIES LLC 513,444 3 21.43%


AUGUST 2017 .. IPIX Volume ~ 3,276,355
9 MMs' reporting ..
( NITE .. CDEL .. ETRF @ 33% .. 29% .. 21% ) .. total = 84.14% of *volume*
( VERT @ 9% )
( LAFC .. CANT .. CSTI all @ 2% )
( PUMA .. VNDM @ sub 1% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	3,276,355	4,896,207	44,092,820	NITE	VIRTU AMERICAS LLC	1,099,604	1	33.56% 
IPIX Innovation Pharma 3,276,355 4,896,207 44,092,820 CDEL CITADEL SECURITIES LLC 959,917 2 29.3%
IPIX Innovation Pharma 3,276,355 4,896,207 44,092,820 ETRF G1 EXECUTION SVCs, LLC 697,321 3 21.28%


JULY 2017 .. IPIX Volume ~ 4,896,207
10 MMs' reporting ..
( CDEL .. NITE .. ETRF @ 35% .. 31% .. 12% ) .. total = 80.42% of *volume*
( CSTI/CANT @ 6% per .. CANT .. LAFC @ 4% .. 2% )
( ARCA PUMA MAXM all @ sub 1% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	4,896,207	6,863,055	40,816,465	CDEL	CITADEL SECURITIES LLC	1,752,747	1	35.8% 
IPIX Innovation Pharma 4,896,207 6,863,055 40,816,465 NITE VIRTU AMERICAS LLC 1,559,023 2 31.84%
IPIX Innovation Pharma 4,896,207 6,863,055 40,816,465 ETRF G1 EXECUTION SVCs, LLC 625,666 3 12.78%


JUNE 2017 (note now IPIX) .. IPIX Volume ~ 6,863,055
11 MMs' reporting ..
( CDEL .. NITE .. ETRF @ 37% .. 30% .. 12% ) .. total = 80.50% of *volume*
( CSTI .. CANT .. LAFC .. @ 8% .. 4% .. 3% )
( ARCA .. MAXM .. PUMA .. VNDM .. MICA all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 IPIX	Innovation Pharma	6,863,055	5,182,012	35,920,258	CDEL	CITADEL SECURITIES LLC	2,569,233	1	37.44% 
IPIX Innovation Pharma 6,863,055 5,182,012 35,920,258 NITE KCG AMERICAS LLC 2,078,242 2 30.28%
IPIX Innovation Pharma 6,863,055 5,182,012 35,920,258 ETRF G1 EXECUTION SVCs, LLC 877,231 3 12.78%


MAY 2017 .. CTIX ( 52 week low *reset* to 63c on 5.10.17 ) Volume ~ 5,182,012
13 MMs' reporting ..
( CDEL .. NITE .. ETRF @ 43% .. 14% .. 11% ) .. total = 69.69% of *volume*
( ARCA & CSTI @ 10% .. CANT @ 5% )
( ARXS .. PUMA .. LAFC .. STXG .. VNDM .. MAXM .. FTBR all @ sub 2% )

Symbol
Issue Name
Market
Tot. Volume (Last Month)
Tot. Volume (2 Months Ago)
Tot. Volume (YTD)
MPID
Market Participant Name
MP Volume
Rank
% Of Total Volume

 CTIX	Cellceutix Corp	5,182,012	6,320,318	29,057,203	CDEL	CITADEL SECURITIES LLC	2,254,605	1	43.51% 
CTIX Cellceutix Corp 5,182,012 6,320,318 29,057,203 NITE KCG AMERICAS LLC 736,389 2 14.21%
CTIX Cellceutix Corp 5,182,012 6,320,318 29,057,203 ETRF G1 EXECUTION SVCs, LLC 620,365 3 11.97%


none of this data is difficult to digest .. but it is time consuming which imo is exactly what NR counts on with *retail*

http://otce.finra.org/MonthlyShareVolume


currently ..

Detailed Quote:IPIX
INNOVATION PHARMACEUTICALS INC
0.355Down -0.007 (-1.93 %)AS OF 1:13:47PM ET 05/10/2018

Last Trade 0.355
Trade Time 1:13:47pm ET

Change -0.007
% Change -1.93%

Bid 0.355
Bid Size 10000

Ask 0.3599
Ask Size 5000


Open 0.369
Day High 0.369
Day Low 0.352
Previous Close
05/09/2018 0.362
52-Week High
12/06/2017 1.17
52-Week Low
05/09/2018 0.35


Price Performance (Last 52 Weeks)
05/09/2018 -45.56%


Volume 433,110
Volume (10 day Average) 281,349
Volume (90 day Average) 217,466

Market Capitalization $52.74M


ETRF 0.355 10,000 13:13
CDEL 0.351 6,500 13:03
LAFC 0.351 2,500 12:58
NITE 0.35 8,845 11:08
CSTI 0.34 100,000 11:07
STXG 0.30 2,500 04/17
VNDM 0.30 2,500 05/09
VERT 0.30 2,500 09:48
CANT 0.14 5,000 08:30
PUMA 0.0001 10,000 08:10
MAXM 0.0001 10,000 09:18
DBOX U 0 04/16
OTCX U 0 09:30

CDEL 0.3599 2,500 13:03
LAFC 0.365 10,000 12:58
CSTI 0.37 2,500 08:30
OTCX 0.375 6,000 10:15
NITE 0.38 8,500 12:57
CANT 0.423 2,500 08:30
PUMA 0.50 2,500 08:10
ETRF 0.52 6,000 12:57
VERT 0.66 1,000 05/08
VNDM 1.00 100 05/09
MAXM 1.95 100 09:18
STXG 2.00 100 10/05
DBOX U 0 04/16


4kids

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 126

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 332

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 731

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 385

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 534

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 398

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 270

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Madison Achieves Top Rank for Employment Opportunities

Updated Category News Views 256

Madison Tops Functional Employment Rankings Recently, Madison has been recognized as the leading metro area in the country for functional employment, a title derived from a comprehensive analysis by the Ludwig Institute for Shared Economic Prosperity (LISEP). This achievement highlights Madison’s robust job growth, higher wage levels, and an overall favorable work...

Continue Reading
Investors Alert: Class Actions Against WEBTOON, Elanco, and Domino's

Updated Category News Views 131

Class Action Lawsuits Overview In recent developments, Bragar Eagel & Squire, P.C., a well-known shareholder rights law firm, has informed investors about multiple class action lawsuits filed against notable companies such as WEBTOON Entertainment, Inc. (NASDAQ: WBTN), Elanco Animal Health Incorporated (NYSE: ELAN), and Domino's Pizza, Inc. (NYSE: DPZ). Shareholders in...

Continue Reading
Navigating the New Multipolar Reality: Insights for Investors

Updated Category News Views 257

The Shift to a Multipolar World: What Investors Need to Know The global landscape has transformed, moving away from a system dominated by one major power to a multipolar world. This significant shift means that traditional geopolitical assumptions guiding investors are no longer reliable. Marko Papic, Chief Strategist at BCA Research, recently underscored this point in a...

Continue Reading
Jim Cramer Discusses Broadcom's Impact on Market Corrections

Updated Category News Views 211

Market Dynamics and Broadcom's Recent Performance As the Nasdaq 100 index faces a notable correction, Broadcom Inc. (NASDAQ: AVGO) has managed to stand out with a remarkable surge of 12.82% during after-hours trading. However, renowned market analyst Jim Cramer expresses skepticism regarding its ability to reverse the overall market decline. Understanding the Market...

Continue Reading
NSFOCUS Achieves 'Stars Companies' Recognition in DDoS Sector

Updated Category News Views 137

NSFOCUS Achieves Notable Recognition in Cybersecurity In a significant development, NSFOCUS has earned recognition as a 'Stars Company' in the DDoS Protection and Mitigation Security sector by the esteemed MarketsandMarkets' 360Quadrants platform. This accolade reflects NSFOCUS's unwavering commitment to innovation and excellence in delivering cutting-edge solutions for...

Continue Reading